Caris Life Sciences

Precision medicine pioneer Caris Life Sciences added 360,000 human life-years to the planet in 2025.

Dr. David Spetzler, MS, Ph.D., MBA

President

A New Way to Fight Cancer

Caris Life Sciences created a new industry for fighting disease by introducing precision medicine to the world.

Cancer. It’s an ugly word. A word you don’t want to hear. Yet, it’s a word that connects us all. At some point, in one way or another, cancer will touch our lives. However, what connects us can also be a driver for change.

That’s why Phoenix-based Caris Life Sciences introduced precision medicine to the world. Guided by the vision of using molecular science to better understand and treat cancer, and an unwavering devotion to help their patients — Caris asks, “What would I do if this patient was my mom?” — an entire industry was born.

How Precision Medicine Saves Lives

The root cause for nearly every type of disease is that an error has occurred somewhere in the body. Nestled deep in our molecular coding is a universe of biological networks that provide the source of life. From how our cells grow, divide, and even die, this biological web holds the keys to better detect, categorize, treat and inform healthcare in an entirely new way. Caris has created the way to analyze and unravel the complexity of disease. This convergence of sequencing power, data and AI technologies provides an unmatched resource to develop the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

With the number of lives saved in 2025, Caris Life Sciences added 360,000 years of life back to its patients.

In 2025, Caris Life Sciences added 360,000 years of life back to its patients.

“Caris was built for one reason — to improve the human condition,” said Chairman, Founder and CEO David Dean Halbert, DSc (h.c.). “Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work — the patient.”

Caris Life Sciences spun out of the Translational Genomics Research Institute (TGEN) at the Phoenix Bioscience Core in 2004 and acquired the Molecular Profiling Institute from TGEN in 2008. Since, it has evolved into a leading patient-centric, next-generation AI TechBio company with 1,500 employees in Arizona.

Driven by a decade of innovation to help build a better world, Caris pushes the boundaries of what is possible and is leading a revolution in healthcare through its connections to more than 95 cancer institutions within their alliance sharing a common goal of improving the human condition across multiple diseases.

Pushing the Boundaries of What is Possible

Caris has built a portfolio of precision medicine tools that have helped more than half-million cancer patients worldwide, with more than 6.5 million tests and over 50 billion molecular markers measured, giving patients more hours on the planet and more time with their families and loved ones.